Li Hong-Shuai, Yang Li-Li, Zhang Ming-Yi, Cheng Ke, Chen Ye, Liu Ji-Yan
Department of Biotherapy, Cancer Center, and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
Sichuan Clinical Research Center of Biotherapy, Chengdu, China.
Front Oncol. 2020 Oct 26;10:548867. doi: 10.3389/fonc.2020.548867. eCollection 2020.
Human epidermal growth factor receptor 2 (HER2) has been verified as a valuable biomarker and treatment target in metastatic colorectal cancer (mCRC). Pyrotinib, a novel irreversible HER2/epidermal growth factor receptor (EGFR) dual tyrosine kinase inhibitor, can efficiently inhibit the proliferation of HER2-positive cancer cells in many tumors. We report a case of a 40-year-old woman with both HER2- and EGFR-amplified metastatic colon cancer, who developed refractory disease resistant to multiline therapies (including trastuzumab with lapatinib) but achieved a remarkable response after pyrotinib treatment. For patients with HER2-positive mCRC, who have developed resistance to trastuzumab and lapatinib, pyrotinib is a promising new candidate, which can be used as salvage therapy.
人表皮生长因子受体2（HER2）已被证实是转移性结直肠癌（mCRC）中有价值的生物标志物和治疗靶点。吡咯替尼是一种新型不可逆的HER2/表皮生长因子受体（EGFR）双靶点酪氨酸激酶抑制剂，可有效抑制多种肿瘤中HER2阳性癌细胞的增殖。我们报告了一例40岁女性患者，患有HER2和EGFR扩增的转移性结肠癌，对多种治疗方案（包括曲妥珠单抗联合拉帕替尼）耐药，但在接受吡咯替尼治疗后取得了显著疗效。对于对曲妥珠单抗和拉帕替尼耐药的HER2阳性mCRC患者，吡咯替尼是一种有前景的新选择，可作为挽救治疗药物。
